NYSEAMERICAN:TRXC - TransEnterix Stock Price, Forecast & News

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

TransEnterix, Inc. (NYSEAMERICAN:TRXC) announced its quarterly earnings results on Tuesday, November, 12th. The medical instruments supplier reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.02. The medical instruments supplier earned $2.02 million during the quarter, compared to analysts' expectations of $4.68 million. View TransEnterix's Earnings History.

TransEnterix is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for TransEnterix.

3 analysts have issued 12 month price objectives for TransEnterix's stock. Their forecasts range from $1.00 to $3.00. On average, they expect TransEnterix's stock price to reach $1.87 in the next year. This suggests a possible upside of 30.5% from the stock's current price. View Analyst Price Targets for TransEnterix.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TransEnterix.

Media headlines about TRXC stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TransEnterix earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for TransEnterix.

TransEnterix saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,380,000 shares, an increase of 14.4% from the December 15th total of 2,080,000 shares. Based on an average daily volume of 424,700 shares, the days-to-cover ratio is currently 5.6 days. Approximately 15.4% of the shares of the company are sold short. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include SDI (SDI), Milestone Scientific (MLSS), IsoRay (ISR), Retractable Technologies (RVP), Impression Healthcare (IHL), TSO3 (TOS), Daxor (DXR), Daxor (DXR), G Medical (GMV), Omega Diagnostics Group (ODX), Akers Biosciences (AKR), Vigil Health Solutions (VGL), Relevium Technologies (RLV), Ambu A/S (AMBBY) and ANSELL LTD/S (ANSLY).

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Opko Health (OPK) and Advanced Micro Devices (AMD).

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $1.43.

TransEnterix has a market capitalization of $28.11 million. View Additional Information About TransEnterix.

The official website for TransEnterix is http://www.transenterix.com/.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.